Clinical trial
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00478114 · Mahidol University, Other · Completed
Key facts
| NCT number | NCT00478114 |
|---|---|
| Title | Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) |
| Official title | An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Mahidol University, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | sorafenib |
| Enrollment | 15 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | May 24, 2007 |
| Last update posted | Aug 29, 2011 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: